Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Biomed Pharmacother ; 111: 1074-1087, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30841421

RESUMEN

Annona vepretorum is an endemic species of the Caatinga biome, known in Northeastern Brazil as "araticum" and/or "pinha da Caatinga". In the present study it was evaluated the neuropharmacological potential of the essential oil obtained from the leaves of Annona vepretorum, as well as of the inclusion complexes of oil obtained with cyclodextrin. Thus, were used neuropharmacological tests already consolidated in the literature like open-field, elevated plus maze, rota-rod, tail suspension test, thiopental-induced sleep test, among others. The acute treatment of essential oil (EO) has anxiolytic, sedative, antiepileptic and antidepressant effects. The anxiolytic and anticonvulsant effects seems to be related to the GABAergic system, probably in the receptor subtypes that mediate the effects of the benzodiazepines, to generate anxiolytic activity. The sedative effect seems to be involved with other signaling pathways. The antidepressant effect of EO seems to be related to its action on serotonergic receptors. It was verified that some behavioral parameters were improved with the oil complexed with ß-cyclodextrin, but this effect was not uniform for all the doses and tests used. Further studies are needed in order to use other options for drug delivery systems. Thus, the essential oil of Annona vepretorum is a promising agent with neurobiological activity and a potential target for drug discovery, since the natural products such as medicinal plants have been a source of new therapeutic proposals.


Asunto(s)
Annona/química , Ansiolíticos/farmacología , Anticonvulsivantes/farmacología , Antidepresivos/farmacología , Neuronas GABAérgicas/efectos de los fármacos , Hipnóticos y Sedantes/farmacología , Aceites Volátiles/farmacología , Neuronas Serotoninérgicas/efectos de los fármacos , Animales , Ansiedad/tratamiento farmacológico , Conducta Animal/efectos de los fármacos , Masculino , Ratones , Extractos Vegetales/farmacología , Hojas de la Planta/química , Plantas Medicinales/química , Transducción de Señal/efectos de los fármacos
2.
PLoS One ; 13(7): e0199009, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30059558

RESUMEN

Pain and inflammation are complex clinical conditions that are present in a wide variety of disorders. Most drugs used to treat pain and inflammation have potential side effects, which makes it necessary to search for new sources of bioactive molecules. In this paper, we describe the ability of LASSBio-1586, an N-acylhydrazone derivative, to attenuate nociceptive behavior and the inflammatory response in mice. Antinociceptive activity was evaluated through acetic acid-induced writhing and formalin-induced nociception tests. In these experimental models, LASSBio-1586 significantly (p<0.05) reduced nociceptive behavior. Several methods of acute and chronic inflammation induced by different chemical (carrageenan, histamine, croton oil, arachidonic acid) and physical (cotton pellet) agents were used to evaluate the anti-inflammatory effect of LASSBio-1586. LASSBio-1586 exhibited potent anti-inflammatory activity in all tests (p<0.05). Study of the mechanism of action demonstrated the possible involvement of the nitrergic, serotonergic and histamine signaling pathways. In addition, a molecular docking study was performed, indicating that LASSBio-1586 is able to block the COX-2 enzyme, reducing arachidonic acid metabolism and consequently decreasing the production of prostaglandins, which are important inflammatory mediators. In summary, LASSBio-1586 exhibited relevant antinociceptive and anti-inflammatory potential and acted on several targets, making it a candidate for a new multi-target oral anti-inflammatory drug.


Asunto(s)
Analgésicos/farmacología , Antiinflamatorios no Esteroideos/farmacología , Inhibidores de la Ciclooxigenasa 2/farmacología , Edema/tratamiento farmacológico , Hidrazonas/farmacología , Nocicepción/efectos de los fármacos , Dolor Nociceptivo/tratamiento farmacológico , Ácido Acético , Analgésicos/síntesis química , Animales , Antiinflamatorios no Esteroideos/síntesis química , Ácido Araquidónico/administración & dosificación , Carragenina/administración & dosificación , Aceite de Crotón/administración & dosificación , Ciclooxigenasa 2/química , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa 2/síntesis química , Dexametasona/farmacología , Modelos Animales de Enfermedad , Edema/inducido químicamente , Edema/metabolismo , Edema/patología , Formaldehído , Miembro Posterior , Histamina/administración & dosificación , Hidrazonas/síntesis química , Indometacina/farmacología , Inflamación , Masculino , Ratones , Simulación del Acoplamiento Molecular , NG-Nitroarginina Metil Éster/farmacología , Dolor Nociceptivo/inducido químicamente , Dolor Nociceptivo/metabolismo , Dolor Nociceptivo/fisiopatología , Ondansetrón/farmacología , Prostaglandinas/biosíntesis
3.
Oxid Med Cell Longev ; 2018: 7043213, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29861833

RESUMEN

Alzheimer's and Parkinson's diseases are considered the most common neurodegenerative disorders, representing a major focus of neuroscience research to understanding the cellular alterations and pathophysiological mechanisms involved. Several natural products, including flavonoids, are considered able to cross the blood-brain barrier and are known for their central nervous system-related activity. Therefore, studies are being conducted with these chemical constituents to analyze their activities in slowing down the progression of neurodegenerative diseases. The present systematic review summarizes the pharmacological effects of flavonoids in animal models for Alzheimer's and Parkinson's diseases. A PRISMA model for systematic review was utilized for this search. The research was conducted in the following databases: PubMed, Web of Science, BIREME, and Science Direct. Based on the inclusion criteria, 31 articles were selected and discussed in this review. The studies listed revealed that the main targets of action for Alzheimer's disease therapy were reduction of reactive oxygen species and amyloid beta-protein production, while for Parkinson's disease reduction of the cellular oxidative potential and the activation of mechanisms of neuronal death. Results showed that a variety of flavonoids is being studied and can be promising for the development of new drugs to treat neurodegenerative diseases. Moreover, it was possible to verify that there is a lack of translational research and clinical evidence of these promising compounds.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Flavonoides/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Proteínas Quinasas Activadas por AMP/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/metabolismo , Animales , Flavonoides/metabolismo , Flavonoides/farmacología , Humanos , Óxido Nítrico Sintasa/metabolismo , Estrés Oxidativo/efectos de los fármacos , Enfermedad de Parkinson/patología , Especies Reactivas de Oxígeno/metabolismo
4.
J Ethnopharmacol ; 221: 65-76, 2018 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-29627297

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Croton conduplicatus Kunth (Euphorbiaceae) is a Brazilian aromatic medicinal plant, widely known as "quebra-faca". In folk medicine, its leaves and stem-barks are used as a natural analgesic for the treatment of headaches. AIM OF THE STUDY: In this study, we describe for the first time the neuropharmacological potential of the essential oil obtained from the leaves of Croton conduplicatus (EO) in experimental models of pain, anxiety and insomnia. The mechanisms of action involved in these activities were also investigated. MATERIAL AND METHODS: Different experimental models were used to evaluate the antinociceptive (acetic acid, formalin-induced nociception and hot plate tests), anxiolytic (elevated plus maze and hole board tests) and sedative (thiopental-induced sleeping time) effects of EO in mice. EO was evaluated in three different doses (25, 50 and 100 mg/kg, i.p.) and compared with positive and negative controls in all experimental protocols. When appropriate, animals were pretreated with pharmacological antagonists (naloxone, atropine and flumazenil) in order to evaluate the mechanisms of action involved. A docking study also was performed to identify possible targets involved. RESULTS: EO (25, 50 and 100 mg/kg, i.p.) demonstrated a significant antinociceptive activity in all experimental models. Pretreatment with naloxone or atropine reversed the antinociceptive response (p < 0.05), suggesting the involvement of opioid and muscarinic receptors, respectively. A docking study was performed with the major components identified in EO (1,8 cineole - 21.42%, spathulenol - 15.47%, p-cymene - 12.41% and caryophyllene oxide - 12.15%), demonstrating favorable interaction profile with different subtypes of muscarinic (M2, M3 and M4) and opioids (delta and mu) receptors. EO also showed anxiolytic (mainly at doses of 25 and 50 mg/kg, i.p.) and sedative (only at the dose of 100 mg/kg, i.p.) effects in mice. These pharmacological responses were reversed by flumazenil (p < 0.05), indicating possible involvement of GABAA receptors. CONCLUSION: Our findings support the traditional use of this plant as a natural analgesic and suggest that EO is a multi-target natural product, presenting not only antinociceptive effect but also anxiolytic and sedative activities depending on the dose used.


Asunto(s)
Analgésicos , Ansiolíticos , Croton , Hipnóticos y Sedantes , Aceites Volátiles , Analgésicos/análisis , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Ansiolíticos/análisis , Ansiolíticos/farmacología , Ansiolíticos/uso terapéutico , Ansiedad/tratamiento farmacológico , Hipnóticos y Sedantes/análisis , Hipnóticos y Sedantes/farmacología , Hipnóticos y Sedantes/uso terapéutico , Masculino , Ratones , Simulación del Acoplamiento Molecular , Aceites Volátiles/análisis , Aceites Volátiles/farmacología , Aceites Volátiles/uso terapéutico , Dolor/tratamiento farmacológico , Fitoquímicos/análisis , Fitoquímicos/farmacología , Fitoquímicos/uso terapéutico , Fitoterapia , Hojas de la Planta , Receptores de GABA-A/metabolismo , Receptores Muscarínicos/metabolismo , Receptores Opioides/metabolismo , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico
5.
Expert Opin Ther Pat ; 28(1): 81-92, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28965471

RESUMEN

INTRODUCTION: Depression is a serious mood disorder and is one of the most common mental illnesses. Despite the availability of several classes of antidepressants, a substantial percentage of patients are unresponsive to these drugs, which have a slow onset of action in addition to producing undesirable side effects. Some scientific evidence suggests that cyclodextrins (CDs) can improve the physicochemical and pharmacological profile of antidepressant drugs (ADDs). The purpose of this paper is to disclose current data technology prospects involving antidepressant drugs and cyclodextrins. AREAS COVERED: We conducted a patent review to evaluate the antidepressive activity of the compounds complexed in CDs, and we analyzed whether these complexes improved their physicochemical properties and pharmacological action. The present review used 8 specialized patent databases for patent research, using the term 'cyclodextrin' combined with 'antidepressive agents' and its related terms. We found 608 patents. In the end, considering the inclusion criteria, 27 patents reporting the benefits of complexation of ADDs with CDs were included. EXPERT OPINION: The use of CDs can be considered an important tool for the optimization of physicochemical and pharmacological properties of ADDs, such as stability, solubility and bioavailability.


Asunto(s)
Antidepresivos/administración & dosificación , Ciclodextrinas/química , Diseño de Fármacos , Animales , Antidepresivos/química , Antidepresivos/farmacocinética , Disponibilidad Biológica , Depresión/tratamiento farmacológico , Excipientes/química , Humanos , Patentes como Asunto , Solubilidad
6.
Molecules ; 22(6)2017 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-28556808

RESUMEN

Medicinal plants have been widely used in the treatment of chronic pain. In this study, we describe the antinociceptive effect of the essential oil from Croton conduplicatus (the EO 25, 50, and 100 mg/kg, i.p.), a medicinal plant native to Brazil. Antinociceptive activity was investigated by measuring the nociception induced by acetic acid, formalin, hot plate and carrageenan. A docking study was performed with the major constituents of the EO (E-caryophyllene, caryophyllene oxide, and camphor). The EO reduced nociceptive behavior at all doses tested in the acetic acid-induced nociception test (p < 0.05). The same was observed in both phases (neurogenic and inflammatory) of the formalin test. When the hot-plate test was conducted, the EO (50 mg/kg) extended the latency time after 60 min of treatment. The EO also reduced leukocyte migration at all doses, suggesting that its antinociceptive effect involves both central and peripheral mechanisms. Pretreatment with glibenclamide and atropine reversed the antinociceptive effect of the EO on the formalin test, suggesting the involvement of KATP channels and muscarinic receptors. The docking study revealed a satisfactory interaction profile between the major components of the EO and the different muscarinic receptor subtypes (M2, M3, and M4). These results corroborate the medicinal use of C. conduplicatus in folk medicine.


Asunto(s)
Analgésicos/farmacología , Croton/química , Aceites Volátiles/farmacología , Extractos Vegetales/farmacología , Plantas Medicinales/química , Analgésicos/química , Animales , Movimiento Celular/efectos de los fármacos , Canales KATP/química , Canales KATP/metabolismo , Leucocitos/efectos de los fármacos , Ratones , Modelos Moleculares , Conformación Molecular , Nocicepción/efectos de los fármacos , Aceites Volátiles/química , Extractos Vegetales/química , Unión Proteica , Receptores Muscarínicos/química , Receptores Muscarínicos/metabolismo , Relación Estructura-Actividad
7.
Pharmacogn Mag ; 11(43): 615-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26246740

RESUMEN

BACKGROUND: Annona vepretorum (AV) is a native tree from Caatinga biome (semiarid region of Brazil) popularly known as "araticum" and "pinha da Caatinga." OBJECTIVE: This study was carried out to evaluate the chemical constituents and antioxidant activity (AA) of the essential oil from the leaves from AV (EO-Av) collected in Petrolina, Pernambuco, Brazil. MATERIALS AND METHODS: Fresh leaves of AV were cut into pieces, and subjected to distillation for 2 h in a clevenger-type apparatus. Gas chromatograph (GC) analyses were performed using a mass spectrometry/flame ionization detector. The identification of the constituents was assigned on the basis of comparison of their relative retention indices. The antioxidant ability of the EO was investigated through two in vitro models such as radical scavenging activity using 2,2-diphenyl-1-picrylhydrazyl method and ß-carotene-linoleate-model system. The positive controls (ascorbic acid, butylated hydroxyanisole and butylated hydroxytoluene) were those using the standard solutions. Assays were carried out in triplicate. RESULTS: The oil showed a total of 21 components, and 17 were identified, representing 93.9% of the crude EO. Spathulenol (43.7%), limonene (20.5%), caryophyllene oxide (8.1%) and α-pinene (5.5%) were found to be the major individual constituents. Spathulenol and caryophyllene oxide could be considered chemotaxonomic markers of these genera. The EO demonstrated weak AA.

8.
Oxid Med Cell Longev ; 2015: 171756, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25653736

RESUMEN

BACKGROUNDS: Oxidative stress can result from excessive free-radical production and it is likely implicated as a possible mechanism involved in the initiation and progression of epileptogenesis. Flavonoids can protect the brain from oxidative stress. In the central nervous system (CNS) several flavonoids bind to the benzodiazepine site on the GABAA-receptor resulting in anticonvulsive effects. OBJECTIVE: This review provides an overview about the role of flavonoids in oxidative stress in epilepsy. The mechanism of action of flavonoids and its relation to the chemical structure is also discussed. RESULTS/CONCLUSIONS: There is evidence that suggests that flavonoids have potential for neuroprotection in epilepsy.


Asunto(s)
Anticonvulsivantes/farmacología , Epilepsia/patología , Flavonoides/farmacología , Estrés Oxidativo/efectos de los fármacos , Animales , Anticonvulsivantes/uso terapéutico , Barrera Hematoencefálica/metabolismo , Sistema Nervioso Central/metabolismo , Epilepsia/tratamiento farmacológico , Epilepsia/metabolismo , Flavonoides/metabolismo , Flavonoides/uso terapéutico , Antagonistas de Receptores de GABA-A/farmacología , Antagonistas de Receptores de GABA-A/uso terapéutico , Humanos , Receptores de GABA-A/química , Receptores de GABA-A/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA